Ponatinib is a tyrosine kinase inhibitor that inhibits tumor cell proliferation by targeting and inhibiting the activity of the BCR-ABL fusion protein (including the T315I mutant) and other kinases (such as VEGFR, PDGFR, FGFR, etc.), blocking abnormal signal transduction.
Ponatinib's Efficacy and Uses
1. Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (ALL)
Newly diagnosed Philadelphia chromosome-positive ALL, used in combination with chemotherapy.
As monotherapy, for patients with Philadelphia chromosome-positive ALL who have no other kinase inhibitors available or who are T315I-positive.
2. Chronic Myeloid Leukemia (CMLE)
Chronic phase CMLE that is resistant to or intolerant to at least two prior kinase inhibitors.
Accelerated phase or blast crisis CMLE that has no other kinase inhibitors available.
T315I-positive CMLE.
Usage Restrictions: Ponatinib is not indicated for, and is not recommended for, the treatment of newly diagnosed chronic myeloid leukemia (CML) in the chronic phase.
Ponatinib Dosage and Administration
1. Recommended Dose for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (ALL):
The starting dose is 30 mg orally once daily in combination with chemotherapy. After achieving complete remission with minimal residual disease negativity at the end of induction therapy, the dose should be reduced to 15 mg orally once daily.
2. Recommended Dose for Monotherapy in T315I-positive Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia for Patients Without Other Kinase Inhibitors:
The starting dose is 45 mg orally once daily.
3. Recommended Dose for Chronic Myeloid Leukemia in the Chronic Phase:
The starting dose is 45 mg orally once daily. After achieving a BCR::ABL1 international normalized ratio ≤1%, the dose should be reduced to 15 mg orally once daily.
4. Recommended Dose for Accelerated and Blast-Transition Chronic Myeloid Leukemia:
The starting dose is 45 mg orally once daily.
Precautions for Ponatinib
1. Hypertension
Monitor blood pressure and manage hypertension according to clinical indications. If hypertension is not controlled by medical means, discontinue administration, reduce the dose, or discontinue ponatinib.
2. Pancreatitis
Monitor serum lipase. Depending on the severity, discontinue administration and then resume medication at the same or reduced dose, or discontinue ponatinib. When lipase is elevated and accompanied by abdominal symptoms, evaluate for pancreatitis.
3. Neuropathy
Monitor for symptoms of peripheral neuropathy and cranial nerve neuropathy. Depending on the recurrence/severity, discontinue administration and then resume medication at the same or reduced dose, or discontinue ponatinib.
4. Ocular Toxicity
Perform a comprehensive ophthalmological examination before treatment initiation and regularly during treatment.
5. Bleeding
Monitor for bleeding and manage the patient according to clinical indications. Depending on the recurrence/severity, discontinue administration and then resume medication at the same or reduced dose, or discontinue ponatinib.
6. Fluid Retention
Monitor for fluid retention and manage the patient according to clinical indications. Depending on the relapse/severity, interrupt treatment and then resume at the same or reduced dose, or discontinue ponatinib.
7. Cardiac Arrhythmias
Monitor for signs or symptoms of cardiac arrhythmias and manage the patient according to clinical indications. Depending on the relapse/severity, interrupt treatment and then resume at the same or reduced dose, or discontinue ponatinib.
8. Myelosuppression
Obtain a complete blood count every 2 weeks for the first 3 months of treatment, then monthly or as clinically indicated. If the absolute neutrophil count is below 1.0 x 10⁹/L or the platelet count is below 50 x 10⁹/L, interrupt ponatinib treatment until the absolute neutrophil count reaches at least 1.5 x 10⁹/L and the platelet count reaches at least 75 x 10⁹/L, then resume treatment at the same or reduced dose.
9. Tumor lysis syndrome
Ensure adequate hydration and correct elevated uric acid levels before initiating ponatinib treatment.
10. Reversible posterior leukoencephalopathy syndrome
If this occurs, ponatinib treatment should be discontinued until remission. The safety of resuming ponatinib after symptom relief is unknown.
